296 results
8-K
SAVA
Cassava Sciences Inc
13 May 24
Submission of Matters to a Vote of Security Holders
4:30pm
as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024, was ratified based upon the following
8-K
EX-99.1
SAVA
Cassava Sciences Inc
10 May 24
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
4:07pm
) – The DSMB is composed of independent clinical research experts who periodically review interim patient safety data. Routine, scheduled DSMB meetings
8-K
EX-99.1
uvtw7o6lgzm
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
8-K
EX-99.1
nfioqf41 tp
7 Feb 24
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
9:20am
424B2
80p1vj2o l55w9ruv
3 Jan 24
Prospectus for primary offering
4:22pm
8-A12B
EX-4.1
1i5ja
3 Jan 24
Registration of securities on exchange
4:18pm
8-K
EX-4.1
s1np8b
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
8-K
EX-5.1
e2vvy1q4
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
8-A12G
EX-4.1
dxgqsfs fsgziw
2 Jan 24
Registration of securities
9:10am
8-K
EX-99.2
5ds 2hw4t
12 Dec 23
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
9:19am
8-K
yi9 ex6k8z5
11 Dec 23
Cassava Sciences Appoints
4:18pm
8-K
EX-99.1
439ntlni1
11 Dec 23
Cassava Sciences Appoints
4:18pm
8-K
EX-3.4
hyn5xmsrj8rs oxk5778
13 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:17pm